– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to ...
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first ...
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE ...
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology ...
Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating ...
Data Highlight Strong Anti-Tumor Activity Across Multiple Tumor Models and Combination Potential with Other Agents On Track to Submit Investigational New Drug Application for MALT1 Development Candidate to the U.S. ...
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, ...
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, ...
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), ...
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain ...
Copyright © 2015 - 2021 Lifecarenews.in
